CY1109745T1 - Μεθοδος ληψης χαρακτηρισμενων πληθυσμων κυτταρου λαμβανομενων απο μυ και χρησεις - Google Patents

Μεθοδος ληψης χαρακτηρισμενων πληθυσμων κυτταρου λαμβανομενων απο μυ και χρησεις

Info

Publication number
CY1109745T1
CY1109745T1 CY20101100077T CY101100077T CY1109745T1 CY 1109745 T1 CY1109745 T1 CY 1109745T1 CY 20101100077 T CY20101100077 T CY 20101100077T CY 101100077 T CY101100077 T CY 101100077T CY 1109745 T1 CY1109745 T1 CY 1109745T1
Authority
CY
Cyprus
Prior art keywords
cell
muscle tissue
muscles
selecting
taking
Prior art date
Application number
CY20101100077T
Other languages
English (en)
Inventor
Jean-Thomas Vilquin
Jean-Pierre Marolleau
Jacques Tremblay
Isabelle Robert
Brigitte Ternaux
Original Assignee
Assistance Publique, Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique, Hopitaux De Paris filed Critical Assistance Publique, Hopitaux De Paris
Publication of CY1109745T1 publication Critical patent/CY1109745T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/115Basic fibroblast growth factor (bFGF, FGF-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η εφεύρεση αφορά μία μέθοδο λήψης κυτταρικών πληθυσμών που προέρχονται από μυϊκό ιστό και χρήση αυτών στην παρασκευή προϊόντων κυτταρικής θεραπείας. Συνίσταται ιδιαιτέρως από την καλλιέργεια κυττάρων που προηγουμένως έχουν απομακρυνθεί με βιοψία από σκελετικούς μυϊκούς ιστούς, πιστοποίηση των διαφορετικών τύπων κυττάρων που υπάρχουν σε διαφορετικά στάδια καλλιέργειας, επιλογή του σταδίου καλλιέργειας επί τη βάσει του απαιτούμενου πληθυσμού κυττάρου και συλλογή του επιλεγέντος σταδίου κυττάρου για παρασκευή προϊόντος κυτταρικής θεραπείας. Η εφεύρεση αυτή επίσης αφορά κυτταρικούς πληθυσμούς που προέρχονται από μυϊκό ιστό, που λαμβάνονται με την πραγματοποίηση της εν λόγω μεθόδου, όπου ο κυρίαρχος τύπος κυττάρου είναι CD34+, CD15+ ή CD16+ ή HLA κατηγορίας 1+ ή περιλαμβάνει έναν κυτταρικό τύπο διπλά αρνητικό CD56-/CD15- ή μπορεί να περιλαμβάνει κυτταρικούς τύπους μεγαλύτερης μειονότητας CD10+, Stro-1+ και CD117+.
CY20101100077T 2000-06-07 2010-01-26 Μεθοδος ληψης χαρακτηρισμενων πληθυσμων κυτταρου λαμβανομενων απο μυ και χρησεις CY1109745T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007304A FR2810045B1 (fr) 2000-06-07 2000-06-07 Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
EP01943584A EP1292671B9 (fr) 2000-06-07 2001-06-07 Procede d'obtention de populations cellulaires caracterisees d'origine musculaire et utilisations

Publications (1)

Publication Number Publication Date
CY1109745T1 true CY1109745T1 (el) 2014-09-10

Family

ID=8851058

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100077T CY1109745T1 (el) 2000-06-07 2010-01-26 Μεθοδος ληψης χαρακτηρισμενων πληθυσμων κυτταρου λαμβανομενων απο μυ και χρησεις

Country Status (14)

Country Link
US (3) US20040043008A1 (el)
EP (1) EP1292671B9 (el)
JP (1) JP2003535586A (el)
AT (1) ATE449163T1 (el)
AU (2) AU6612701A (el)
BR (1) BR0111497A (el)
CA (1) CA2411762A1 (el)
CY (1) CY1109745T1 (el)
DE (1) DE60140536D1 (el)
DK (1) DK1292671T3 (el)
ES (1) ES2335747T3 (el)
FR (1) FR2810045B1 (el)
PT (1) PT1292671E (el)
WO (1) WO2001094555A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1272204T3 (da) * 2000-04-14 2007-09-10 Univ Pittsburgh Forstærkning og bulking af blödt væv og knoglevæv under anvendelse af muskelafledte progenitorceller, præparater deraf og behandling dermed
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
NZ536290A (en) * 2002-05-10 2006-07-28 Isolagen Technologies Inc Injecting a suspension of histologically compatible, autologous, passaged fibroblasts and muscle cells to treat urinary incontinence and vesicoureteral and oesophageal reflux
WO2004096245A2 (en) * 2003-04-25 2004-11-11 The University Of Pittsburgh Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration
JPWO2006006692A1 (ja) * 2004-07-08 2008-05-01 独立行政法人科学技術振興機構 低血清培養で選択的に増殖する動物組織遍在性の分化多能性細胞
FR2890977A1 (fr) * 2005-09-19 2007-03-23 Assist Publ Hopitaux De Paris Procede d'obtention de cellules musculaires lisses humaines et leurs applications
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
AU2008263134B2 (en) * 2007-05-29 2014-06-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
EP2206774A1 (en) 2008-12-23 2010-07-14 Genzyme Corporation Muscle-derived cells having differentiation capacities
BR112012001107A2 (pt) * 2009-07-09 2015-09-01 Janssen Biotech Inc Células derivadas de tecido cardíaco
FR3074018B1 (fr) 2017-11-27 2020-09-11 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
FR3088541B1 (fr) 2018-11-15 2021-11-05 Lab Francais Du Fractionnement Procede de conservation de cellules a visee therapeutique
CA3142248A1 (en) * 2019-05-31 2020-12-03 Figene, Llc Fibroblast therapy for treatment of duchenne muscular dystrophy
EP4026587A4 (en) * 2019-09-30 2022-11-16 TERUMO Kabushiki Kaisha METHOD OF INCREASING THE PERCENTAGE OF CD56+ CELLS
KR20240085728A (ko) * 2022-12-08 2024-06-17 주식회사 팡세 근육줄기세포의 분화능 예측을 위한 cd56의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5538722A (en) * 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
ES2113344T3 (es) * 1989-08-03 1998-05-01 Univ California Metodo para aislar celulas de citotrofoblastos fetales.
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5196315A (en) * 1990-05-01 1993-03-23 The Johns Hopkins University Human neuronal cell line
WO1994007138A1 (en) * 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
EP0714510B1 (en) * 1993-08-27 2002-06-19 Dana Farber Cancer Institute Natural killer cell-specific antigen and antibodies that identify the same
US6110459A (en) * 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
WO1999049015A2 (en) * 1998-03-23 1999-09-30 Zymogenetics, Inc. Cardiac-derived stem cells
DK1604674T3 (da) * 1998-05-01 2009-03-23 Univ Pittsburgh Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens
US7368420B1 (en) * 1998-10-02 2008-05-06 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Akt compositions for enhancing survival of cells
US6673604B1 (en) * 1999-07-23 2004-01-06 Diacrin, Inc. Muscle cells and their use in cardiac repair
US20030113301A1 (en) * 1999-07-23 2003-06-19 Albert Edge Muscle cells and their use in cardiac repair
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations

Also Published As

Publication number Publication date
FR2810045A1 (fr) 2001-12-14
US20060088508A1 (en) 2006-04-27
JP2003535586A (ja) 2003-12-02
ATE449163T1 (de) 2009-12-15
PT1292671E (pt) 2010-02-05
US20040043008A1 (en) 2004-03-04
DE60140536D1 (de) 2009-12-31
EP1292671B1 (fr) 2009-11-18
EP1292671A1 (fr) 2003-03-19
ES2335747T3 (es) 2010-04-05
WO2001094555A1 (fr) 2001-12-13
BR0111497A (pt) 2004-04-06
US20110014159A1 (en) 2011-01-20
FR2810045B1 (fr) 2004-09-03
EP1292671B9 (fr) 2010-05-19
AU2001266127B2 (en) 2007-01-04
DK1292671T3 (da) 2010-03-15
CA2411762A1 (fr) 2001-12-13
AU6612701A (en) 2001-12-17

Similar Documents

Publication Publication Date Title
CY1109745T1 (el) Μεθοδος ληψης χαρακτηρισμενων πληθυσμων κυτταρου λαμβανομενων απο μυ και χρησεις
CY1106621T1 (el) Μεθοδος για την ανιχνευση του mrna του ανθρωπινου ιου του θηλωματος
CY1122390T1 (el) Μεθοδοι χρησης της il-21 για την προσαρμοστικη ανοσοθεραπεια και την ταυτοποιηση καρκινικων αντιγονων
BR0312764A (pt) Cardiomiócitos funcionais originados de células-tronco embrionárias humanas
HK1079238A1 (en) Selection and isolation of living cells using rna-binding probes
CY1112293T1 (el) Χρηση των il-7 και il-15 για τη γενετικη τροποποιηση μνημονικων τ λεμφοκυτταρων
ES2672895T3 (es) Generación de células T específicas de antígeno
NL300307I1 (nl) Werkwijzen voor de replicatie van influenzavirussen in celkweek en de influenzavirussen die verkrijgbaar zijn met behulp van de werkwijze
ATE516497T1 (de) Screening für funktionshomologien
EP2471904A3 (en) Placental stem cell populations
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
ATE333517T1 (de) Verfahren und sondenset zur erkennung von krebs
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
BR0011132A (pt) Método e "kit" para amostragem e armazenagem de amostras biológicas
DK1960789T3 (da) Detektion af føtale celler maternelt blod
AU2003302732A1 (en) Method for identifying risk of breast cancer and treatments thereof
DE69935999D1 (de) Methoden zur introduktion heterologer zellen in fische
DE69632252D1 (de) Verfahren zur erkennung von klonalen populationen von transformierten zellen in einer genomisch heterogenen zellulären probe
UY28558A1 (es) Proteína
YU90301A (sh) Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane
DE60041340D1 (de) Identifizierung des plasmodium falciparum erythrozn zum chondroitin sulfat a vermittelt
FR2848565B1 (fr) Lignee de cellules dendritiques gen2.2
BRPI0407002A (pt) Células cultivadas que apresentam antìgeno cd14+
MX2020012708A (es) Metodo epigenetico para estimar la edad extrinseca de la piel.
BRPI0311182A2 (pt) método para isolar uma célula endotelial e método para realizar provas cruzadas específicas para o doador